Hinchey decries the lack of FDA reform

Share this article:
Rep. Maurice Hinchey (D-NY) says Congress has refused to act on several bills to reform the FDA, "because members are comfortably obliged to the pharmaceutical industry."
 
But Pharmaceutical Research and Manufacturers of America associate vice president Alan Goldhammer says the issues confronting FDA are complex and “one doesn't want to make dramatic policy changes without a thorough examination.”

Hinchey and Goldhammer were among several people interviewed for a Newark Star-Ledger story on the lack of action on FDA reform.

“We expected more urgency and we wanted more urgency,” said Diana Zuckerman, president of the National Research Center for Women and Families. “There has been a lot of talking, but that's all.”
Later, Hinchey and other lawmakers staged an FDA 100th anniversary media event on June 29 to promote HR 4429, which calls for a new, independent Center for Post-market Drug Evaluation and Research within the FDA.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...